{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:23:09Z","timestamp":1787314989588,"version":"build-2736575974"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed\/refractory B-cell lymphomas, yet its initial use in central nervous system lymphoma has been hampered by safety concerns and limited efficacy. Current data are derived from small, heterogeneous trials, with unresolved questions regarding neurotoxicity mitigation, optimal treatment timing, long-term response durability, and predictive biomarkers, precluding widespread clinical implementation. This narrative review systematically integrates peer-reviewed clinical trials, real-world retrospective datasets and preclinical mechanistic investigations to summarize the efficacy and safety profile of CAR-T in patients with PCNSL and SCNSL.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1858455","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:23:21Z","timestamp":1787311401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in CAR-T therapy for central nervous system lymphoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiumei","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Hematology, The Fourth People\u2019s Hospital of Jinan Affiliated to Shandong Second Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Laboratory of Precision Medicine, The Fourth People\u2019s Hospital of Jinan Affiliated to Shandong Second Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Fourth People\u2019s Hospital of Jinan Affiliated to Shandong Second Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Kai","sequence":"additional","affiliation":[{"name":"Rehabilitation & Health Care Ward, The Fourth People\u2019s Hospital of Jinan Affiliated to Shandong Second Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth People\u2019s Hospital of Jinan Affiliated to Shandong Second Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Key Medical and Health Laboratory of Blood Ecology and Biointelligence, Jinan Key Laboratory of Medical Cell Bioengineering, Science and Technology Innovation Center, The Fourth People\u2019s Hospital of Jinan Affiliated to Shandong Second Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Critical Care, The Fourth People\u2019s Hospital of Jinan, Affiliated to Shandong Second Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leisheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Key Medical and Health Laboratory of Blood Ecology and Biointelligence, Jinan Key Laboratory of Medical Cell Bioengineering, Science and Technology Innovation Center, The Fourth People\u2019s Hospital of Jinan Affiliated to Shandong Second Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.hoc.2019.03.008","article-title":"Central nervous system lymphoma","volume":"33","author":"Chukwueke","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40364-021-00282-z","article-title":"Current and emerging therapies for primary central nervous system lymphoma","volume":"9","author":"Yuan","year":"2021","journal-title":"biomark Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1438001","article-title":"New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.371","article-title":"Long-term complete remission of decitabine-primed tandem CD19\/CD22 CAR-T therapy with PD-1 and BTK inhibitors maintenance in a refractory primary central nervous system lymphoma patient","volume":"55","author":"Zou","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1331844","article-title":"Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data","volume":"14","author":"Zhou","year":"2024","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008553","article-title":"Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed\/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China","volume":"12","author":"Yu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06378-y","article-title":"Whole brain radiotherapy combined with CART-cell therapy for relapsed\/refractory central nervous system B-cell lymphoma","volume":"104","author":"Shi","year":"2025","journal-title":"Ann Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107385","article-title":"The shifting therapeutic paradigm for relapsed\/refractory mantle cell lymphoma","volume":"134","author":"Arun Kumar","year":"2023","journal-title":"Leuk Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2425131","article-title":"Tumor microenvironment in primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Jin","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S519616","article-title":"Current advances and challenges in CAR-T therapy for hematological and solid tumors","volume":"14","author":"Zhang","year":"2025","journal-title":"Immunotargets Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2021.278613","article-title":"Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy","volume":"109","author":"Roschewski","year":"2024","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.22088\/IJMCM.BUMS.13.4.361","article-title":"O-6-methylguanine-DNA methyltransferase, C-MYC, and EBER status in diffuse large B-cell lymphoma of central nervous system","volume":"13","author":"Sadeghipour","year":"2024","journal-title":"Int J Mol Cell Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-024-2783-2","article-title":"Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy","volume":"68","author":"Zhou","year":"2025","journal-title":"Sci China Life Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533444","article-title":"Advances in primary large B-cell lymphoma of immune-privileged sites","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683007","article-title":"Analysis of cellular heterogeneity in immune microenvironment of primary central nervous system lymphoma by single-cell sequencing","volume":"11","author":"Wei","year":"2021","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.211879","article-title":"Advances in pathobiology of primary central nervous system lymphoma","volume":"130","author":"Yang","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-026-00945-9","article-title":"Unraveling the immune microenvironment in primary CNS lymphoma","volume":"14","author":"Lorenzen","year":"2026","journal-title":"biomark Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205061","article-title":"Emerging landscape of immunotherapy for primary central nervous system lymphoma","volume":"13","author":"Alcantara","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02575-y","article-title":"In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy","volume":"69","author":"Marcelis","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1004703","article-title":"The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma","volume":"13","author":"Worel","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215372","article-title":"Update on novel therapeutics for primary CNS lymphoma","volume":"13","author":"Schaff","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/febs.17326","article-title":"Depletion of Tregs from CD4+ CAR-T cells enhances the tumoricidal effect of CD8+ CAR-T cells in anti-CD19 CAR-T therapy","volume":"292","author":"Sun","year":"2025","journal-title":"FEBS J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.08.019","article-title":"Asparaginase enhances CAR-T cell antitumor immunity by asparagine metabolic reprogramming and central memory induction in ALL","volume":"33","author":"Zhu","year":"2025","journal-title":"Mol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0043","article-title":"Chimeric antigen receptor T cells: immunotherapy for the treatment of leukemia, lymphoma, and myeloma","volume":"22","author":"Rodr\u00edguez Gil de Montes","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41586-024-07314-2","article-title":"Brain endothelial GSDMD activation mediates inflammatory BBB breakdown","volume":"629","author":"Wei","year":"2024","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0588","article-title":"Lenalidomide plus R-GDP (R2-GDP) in relapsed\/refractory diffuse large B-cell lymphoma: final results of the R2-GDP-GOTEL trial and immune biomarker subanalysis","volume":"28","author":"Palaz\u00f3n-Carri\u00f3n","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/15330338251319394","article-title":"Molecular mechanisms and therapeutic prospects of immunotherapy and targeted therapy in primary central nervous system lymphoma","volume":"24","author":"Zhong","year":"2025","journal-title":"Technol Cancer Res Treat"},{"key":"B33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13014-022-02142-y","article-title":"The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings","volume":"17","author":"de P\u00e1dua Covas Lage","year":"2022","journal-title":"Radiat Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005602","article-title":"Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement","volume":"6","author":"Akin","year":"2022","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1182\/blood-2025-5455","article-title":"Clinical outcomes associated with conditioning regimens in patients with primary central nervous system lymphoma undergoing consolidation autologous stem cell transplantation","volume":"146","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1008828","article-title":"Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell Malignancies with bulky disease","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1182\/blood-2025-672","article-title":"Prospective phase I\/II study of CD19-directed CAR-t therapy in relapsed\/refractory central nervous system lymphoma: clinical outcomes and safety profile","volume":"146","author":"Li","year":"2025","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00262-024-03855-7","article-title":"Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory\/relapsed primary or secondary central nervous system lymphoma","volume":"74","author":"Wu","year":"2024","journal-title":"Cancer Immunol Immun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.948125","article-title":"A review of CAR T cells and adoptive T-cell therapies in lymphoid and solid organ Malignancies","volume":"31","author":"Parums","year":"2025","journal-title":"Med Sci Monit"},{"key":"B40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00005-020-00599-x","article-title":"The application of CAR-T cells in haematological Malignancies","volume":"68","author":"Skorka","year":"2020","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303215","article-title":"Advances in CAR-engineered immune cell generation: engineering approaches and sourcing strategies","volume":"10","author":"Chen","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem CAR-T cell therapy: recent advances and current challenges","volume":"16","author":"G\u00f3mez-Melero","year":"2025","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2458214","article-title":"CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges","volume":"66","author":"Xiong","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142608","article-title":"The spectrum of CAR cellular effectors: modes of action in anti-tumor immunity","volume":"16","author":"Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910511","article-title":"CAR-T-cell therapy for systemic lupus erythematosus: a comprehensive overview","volume":"25","author":"Abdalhadi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2020.07.015","article-title":"CRISPR\/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy","volume":"158","author":"Huang","year":"2020","journal-title":"Adv Drug Delivery Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological Malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1492552","article-title":"Chimeric antigen receptor T-cell therapy in autoimmune diseases","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06052-3","article-title":"From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy","volume":"23","author":"Pinto","year":"2025","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030190","article-title":"Advances in adoptive cell therapies in cancer: From mechanistic breakthroughs to clinical frontiers and overcoming barriers","volume":"13","author":"Rabbani","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090725","article-title":"State of the art in CAR-T cell therapy for solid tumors: Is there a sweeter future","volume":"13","author":"Amor\u00f3s-P\u00e9rez","year":"2024","journal-title":"Cells"},{"key":"B53","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3892\/ol.2020.12244","article-title":"Latest evidence on immunotherapy for cholangiocarcinoma","volume":"20","author":"Guo","year":"2020","journal-title":"Oncol Lett"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01350","article-title":"CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma","volume":"9","author":"Tu","year":"2019","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2176\/jns-nmc.2022-0134","article-title":"A case of relapsed primary central nervous system lymphoma treated with CD19-directed chimeric antigen receptor T cell therapy","volume":"9","author":"Mizuta","year":"2022","journal-title":"NMC Case Rep J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01306","article-title":"CAR T-cell therapy is effective but not long-lasting in B-cell lymphoma of the brain","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2006","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed\/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL)","volume":"42","author":"Nayak","year":"2024","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167784","article-title":"Efficacy of CAR-T cells in primary central nervous system lymphomas: The French experience of the National LOC Network","volume":"140","author":"Sylvain","year":"2022","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27316","article-title":"CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network","volume":"99","author":"Choquet","year":"2024","journal-title":"Am J Hematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285613","article-title":"Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy","volume":"110","author":"Mercadal","year":"2025","journal-title":"Haematologica"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70375","article-title":"CAR T-cell therapy in patients with primary central nervous system lymphoma: A LOC network study","volume":"101","author":"Bouille","year":"2026","journal-title":"Am J Hematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282875","article-title":"CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes","volume":"108","author":"Lacan","year":"2023","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20234","article-title":"Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience","volume":"207","author":"Cassanello","year":"2025","journal-title":"Br J Haematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70146","article-title":"Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition","volume":"9","author":"Ossami Saidy","year":"2025","journal-title":"Hemasphere"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12967-025-06608-x","article-title":"Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell Malignancies with central nervous system involvement: results of a pivotal trial","volume":"23","author":"He","year":"2025","journal-title":"J Transl Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: Results from the US Lymphoma CAR T Consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01099-4","article-title":"Axicabtagene ciloleucel CAR T-cell therapy for relapsed\/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies","volume":"56","author":"Ghafouri","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200608","article-title":"Toxicities and response rates of secondary CNS lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T cells","volume":"98","author":"Karschnia","year":"2022","journal-title":"Neurology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010336","article-title":"Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA\/DRST study","volume":"7","author":"Ayuk","year":"2023","journal-title":"Blood Adv"},{"key":"B76","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27354","article-title":"Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis","volume":"99","author":"Alsouqi","year":"2024","journal-title":"Am J Hematol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1903854116","article-title":"Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice","volume":"116","author":"Mulazzani","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1158\/2326-6066.CIR-20-0236","article-title":"The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma","volume":"9","author":"Wang","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12672-026-04731-9","article-title":"Next-generation CAR-T and CAR-NK cell therapies in hematologic Malignancies: engineering for persistence, specificity, and safety","volume":"17","author":"Al-Khreisat","year":"2026","journal-title":"Discov Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.1c01532","article-title":"In vitro engineering chimeric antigen receptor macrophages and T cells by lipid nanoparticle-mediated mRNA delivery","volume":"8","author":"Ye","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"key":"B83","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.115064","article-title":"A chemokine \"leverage regulation\" biomimetic nanoformulation enhances CAR-T cells against solid tumors by reshaping immune cell niches","volume":"396","author":"Zhao","year":"2026","journal-title":"J Control Release"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70053","article-title":"Combining small-molecular compounds with CAR T-cell therapy: Novel strategies for enhanced cancer immunotherapy","volume":"5","author":"Yi","year":"2026","journal-title":"Cancer Innov"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102021","article-title":"Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity","volume":"6","author":"Akhtar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ccell.2025.02.004","article-title":"Metabolic engineering to facilitate anti-tumor immunity","volume":"43","author":"Schild","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1858455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:23:22Z","timestamp":1787311402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1858455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2026.1858455"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1858455","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1858455"}}